Poseida Therapeutics To Present New Preclinical Data Supporting Non-Viral Gene Editing With P-KLKB1-101 For The Treatment Of Hereditary Angioedema
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics is set to present new preclinical data on its non-viral gene editing treatment, P-KLKB1-101, for hereditary angioedema at the ACAAI 2024 Scientific Meeting. The data highlights the potential of their Cas-CLOVER™ system for effective and controlled gene editing.
October 24, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Poseida Therapeutics will present promising preclinical data on P-KLKB1-101, a non-viral gene editing treatment for hereditary angioedema, at the ACAAI 2024 meeting. The data supports the potential of their Cas-CLOVER™ system.
The presentation of promising preclinical data at a major scientific meeting could boost investor confidence in Poseida's innovative gene editing technology, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90